Found 44 matching trials
Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer
N/AThis study aim to determine kinetic of post treatment recovery/variation of...
Location
Chu Grenoble Alpes
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
NAPatient with histologically proven NSCLC in a metastatic stage, treatment n...
Location
Hopital Ambroise Pare
Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence
NAStudy comparing 2 modalities of Crohn's disease patients postoperative foll...
Location
CHU de Montpellier
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
NAThe development of Immune Checkpoint Blockade (ICB) is a revolution in medi...
Location
Institut Paoli-Calmettes
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
NAThis project is a framework for developing new therapeutic strategies for a...
Location
Thomas PREBET, MD
Colorectal Cancer Immunomonitoring Combined With Radiofrequency ablatIon
N/AThe primary objective of the study aims to compare soluble CD154 (CD40L) le...
Location
Department of digestive surgery, Ambroise Paré Hospital, APHP
Human Ab Response & immunoMONItoring of COVID-19 Patients
NAProspective, mono centric study on COVID-19 patients with or without acute ...
Immunomonitoring of Circulating Immune Cells in Maxillofacial Surgery
N/AThe immune response following facial reconstruction may help predict healin...
Location
Multiple Locations
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
PHASE3Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. ...
Status
Active Not Recruiting
Immunomonitoring After Hematopoietic Stem Cell Transplantation
N/AAllogeneic hematopoietic stem cell transplantation (HSCT) remains the only ...